Trial Profile
A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ixabepilone (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Therapeutic Use
- 20 Nov 2023 Status changed from active, no longer recruiting to completed.
- 11 Jan 2023 Planned End Date changed from 1 Feb 2028 to 1 Feb 2024.
- 13 Apr 2022 Planned End Date changed from 1 Feb 2027 to 1 Feb 2028.